News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MacroGenics, Inc. Files Paperwork for $60 Million IPO


9/5/2013 8:10:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Rockville-based biotech MacroGenics Inc. filed paperwork Wednesday for a $60 million initial public offering, in what would be the second Washington-area life sciences IPO in recent months. MacroGenics, a clinical-stage biotech focused on oncology, said it would use the proceeds to fund clinical development for margetuximab (also known as MGAH22) — currently in mid-stage trials for metastatic breast cancer and gastroesophageal cancer — and a second product, MGA271. Both are monoclonal antibodies. The cash from the IPO would also go toward advancing MacroGenics' early-stage pipeline.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES